<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832178</url>
  </required_header>
  <id_info>
    <org_study_id>14976</org_study_id>
    <nct_id>NCT04832178</nct_id>
  </id_info>
  <brief_title>Sumor as Adjuvant Therapy in Treatment-resistant Major Depression</brief_title>
  <acronym>SUSCA</acronym>
  <official_title>Use of Sumor in the Antidepressant Therapy of Subjects With Major Depression: a Randomized Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria Careggi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria Careggi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sumor is a food supplement that combines the main coenzymes of the S-Adenosyl methionine&#xD;
      (SAMe) cycle, namely vitamins B6, B12 and folate, with SAMe and betaine. Sumor also contains&#xD;
      vitamin C, a molecule that has shown promise in the treatment of depression in experimental&#xD;
      models, and selenium, an antioxidant agent whose blood deficiency has been associated with&#xD;
      depressive symptoms in some preliminary studies. There are no studies in the literature on&#xD;
      the efficacy of this combination in the adjuvant therapy of depression. The purpose of this&#xD;
      study is to compare the effects of Sumor in co-therapy with an SSRI antidepressant versus&#xD;
      co-therapy with placebo in patients with treatment-resistant Major Depressive Disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression (HAM-D)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The change in total HAM-D score between baseline and the 8-week follow-up was the primary outcomes measure. This measure is a clinician rated inventory of depressive symptoms. All items are scored on scales ranging from 0-2 to 0-4, and the sum of the scores provides the total score for the measure. On this scale, higher scores indicate poorer outcomes. Scores over 24 are considered indicative of severe depressive symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Rating Scale for Depression (HAM-D)</measure>
    <time_frame>Baseline, 2 weeks, and 4 weeks</time_frame>
    <description>The change in total HAM-D score between baseline and the intermediate 2-week and 4-week follow-ups were considered secondary outcomes measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Scale (HAM-A)</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks and 8 weeks</time_frame>
    <description>The change in total HAM-A score between baseline and the 2-week, 4-week and 8-week follow-ups were considered secondary outcomes measures. This measure is a clinician rated inventory of anxiety symptoms. The sum of the scores provides the total score for the measure. On this scale, higher scores indicate poorer outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SIDE</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks and 8 weeks</time_frame>
    <description>A self-assessment questionnaire for undesirable effects in psychopharmacological treatment, developed by the Department of Psychiatry of Vanderbilt University in Nashville. It allows to investigate the presence or absence of 48 symptoms, exploring their severity and the relationship with the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms remission</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks and 8 weeks</time_frame>
    <description>Remission rate of Major Depression in the two groups over the course of treatment, defining remission as a score ≤ 7 on the HAM-D scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SUMOR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SUMOR</intervention_name>
    <description>SUMOR is a food supplement distributed in Italy by ArcaPharma. regularly entered in the register of Food Supplements of the Ministry of Health (number 62590). Formulated in prolonged-release tablets, each tablet contains the following substances:&#xD;
S-Adenosyl-L-Methionine sulfate p-toluenesulfonate 250 mg&#xD;
Betaine hydrochloride 250 mg&#xD;
Vitamin C 80 mg&#xD;
Vitamin B1 1.1 mg&#xD;
Vitamin B2 1.4 mg&#xD;
Vitamin B6 1.4 mg&#xD;
Vitamin B12 2,5 µg&#xD;
Folic Acid 200 µg&#xD;
Selenium 37 µg</description>
    <arm_group_label>SUMOR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet will be identical in appearance to the experimental product (SUMOR).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Major Depressive Disorder according to DSM-5 criteria&#xD;
&#xD;
          -  Treatment-resistant status, assessed by clinical interview, after four weeks after&#xD;
             SSRI therapy prescription as per NICE guidelines (National Institute for Health and&#xD;
             Care Excellence, 2009)&#xD;
&#xD;
          -  Age between 18 and 65 years&#xD;
&#xD;
          -  Signature of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of intellectual disability or illiteracy&#xD;
&#xD;
          -  Diagnosis of a disorder belonging to the spectrum of schizophrenia or other psychotic&#xD;
             disorders according to DSM-5&#xD;
&#xD;
          -  Diagnosis of a disorder belonging to the bipolar spectrum according to DSM-5&#xD;
&#xD;
          -  Concomitant intake of therapy with other antidepressants, antipsychotics or mood&#xD;
             stabilizers at the time of evaluation or in the previous 4 weeks&#xD;
&#xD;
          -  State of pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Rotella, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria Careggi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valdo Ricca, MD</last_name>
    <phone>+390557947478</phone>
    <email>valdo.ricca@unifi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Rotella, PhD, MD</last_name>
      <phone>+390557947478</phone>
      <email>francesco.rotella@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Rotella, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emanuele Cassioli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniele Busatta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria Careggi</investigator_affiliation>
    <investigator_full_name>Francesco Rotella</investigator_full_name>
    <investigator_title>Dirigente Medico 1° livello - Psichiatra</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

